Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cumulative dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    780 result(s) found for: Cumulative dose. Displaying page 3 of 39.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-002715-34 Sponsor Protocol Number: ADN014 Start Date*: 2018-01-30
    Sponsor Name:ADIENNE SA
    Full Title: A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of begelomab as an initial treatment of acute Graft-versus-Host D...
    Medical condition: Acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000160-15 Sponsor Protocol Number: MVT-601-3201 Start Date*: 2017-07-25
    Sponsor Name:Myovant Sciences GmbH
    Full Title: HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
    Medical condition: Androgen-sensitive advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) SK (Completed) DK (Completed) FI (Completed) ES (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000303-42 Sponsor Protocol Number: 9050 Start Date*: 2006-09-25
    Sponsor Name:ISALA KLINIEKEN
    Full Title: A randomized, double blind controlled trial evaluating the benefits of early up-front-loaded high dose Tirofiban in the treatment of patients with ST-segment elevation myocardial infarction, who ar...
    Medical condition: acute myocardial infarction with ST segment elevation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10064345 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002988-18 Sponsor Protocol Number: EFC15068 Start Date*: 2018-11-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) DK (Completed) HU (Completed) FR (Completed) SE (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) PT (Completed) SI (Completed) BE (Prematurely Ended) HR (Completed) GB (GB - no longer in EU/EEA) NO (Completed) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000345-31 Sponsor Protocol Number: NL56584.092.16 Start Date*: 2016-09-30
    Sponsor Name:VU medical center
    Full Title: Towards personalized dosing of natalizumab in multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005110-58 Sponsor Protocol Number: 64024 Start Date*: 2018-06-14
    Sponsor Name:Medical Centre Leeuwarden
    Full Title: Efficacy of a predefined vitamin D dosing regimen in vitamin D-insufficient multiple myeloma patients.
    Medical condition: Hypovitaminosis D
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002641-11 Sponsor Protocol Number: PRIDE Start Date*: 2018-11-21
    Sponsor Name:Sint Maartenskliniek
    Full Title: The BRIDGE-PMR study: B-cell depletion with Rituximab for Dose reduction of Glucocorticoids: Efficacy in PolyMyalgia Rheumatica
    Medical condition: polymyalgia rheumatica
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004979-35 Sponsor Protocol Number: 05-FOR-01 SE Start Date*: 2006-11-27
    Sponsor Name:Andi - Ventis
    Full Title: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS BRONCHODILATION, SAFETY AND TOLERABILITY OF NEW GENERIC DRY POWDER FORMOTEROL FORMULATIONS GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALE...
    Medical condition: reversible mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-000276-40 Sponsor Protocol Number: 04- SAL-02/BS536 Start Date*: 2005-04-22
    Sponsor Name:GENERICS [UK] Ltd.
    Full Title: A RANDOMISED, OPEN TWO WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW SALBUTAMOL-HFA 134a FORMULATION GIVEN AS CUMULATIVE DOSES AND A REFERENCE SALBUTAMOL-HFA 134a FORMULAT...
    Medical condition: Documented asthma for at least 6 months before screening Subjects with a FEV1 of between 50-85% of the predicted normal value for age, height and gender after withholding short acting Beta2-agonist...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000699-24 Sponsor Protocol Number: PHRC2010-03 Start Date*: 2014-10-02
    Sponsor Name:CHU Angers-DAMR
    Full Title: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à do...
    Medical condition: Leucémie aiguë myéloïde
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000839-21 Sponsor Protocol Number: DREPADOL Start Date*: 2019-06-17
    Sponsor Name:Centre Hospitalier Intercommunal de Créteil
    Full Title: Evaluation of the efficacy and safety of aprepitant in the management of vaso-occlusive crisis in sickle cell children: randomized, single-center, randomized, phase IIb/III prospective study
    Medical condition: vaso-occlusive crisis for patients with sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10040644 Sickle cell disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2021-002634-16 Sponsor Protocol Number: NL76533.041.21 Start Date*: 2021-08-25
    Sponsor Name:University Medical Center Utrecht
    Full Title: Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic patients with head and neck squamous cell carcinoma
    Medical condition: The IMP will be used to treat locally advanced head and neck squamous cell carcinoma (HNSCC). Patients with low skeletal muscle mass will be randomized between two schedules: 1) weekly 40 mg/m2 cis...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000826-36 Sponsor Protocol Number: P160905J Start Date*: 2018-05-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Efficacy and safety of immunoglobulin associated with rituximab versus rituximab alone in Childhood-Onset steroid-dependent nephrotic syndrome
    Medical condition: Childhood-Onset steroid-dependent nephrotic syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004257-41 Sponsor Protocol Number: ARC003 Start Date*: 2016-02-10
    Sponsor Name:Aimmune Therapeutics Inc.
    Full Title: PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (THE PALISADE STUDY)
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) DK (Completed) IE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012973-37 Sponsor Protocol Number: IPR/21 Start Date*: 2009-12-03
    Sponsor Name:MOLMED
    Full Title: TK008: Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
    Medical condition: Patients with high risk acute leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060930 Acute leukaemia in remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) NL (Prematurely Ended) BE (Prematurely Ended) HU (Completed) LT (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001177-25 Sponsor Protocol Number: P04057 Start Date*: 2005-02-01
    Sponsor Name:Schering-Plough CE AG Hungarian Commercial Representative Office
    Full Title: Cardiac safety profile of Caelyx therapy in anthracyclin pretreated metastatic breast cancer patients.
    Medical condition: Women with histologically or cytologically confirmed metastatic breast cancer (no prior chemotherapy for metastatic disease).
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004321-95 Sponsor Protocol Number: AMLSG 07-04 Start Date*: 2005-05-26
    Sponsor Name:University of Ulm
    Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI...
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021861-62 Sponsor Protocol Number: BACLAD Start Date*: 2010-12-10
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Baclofen for the Treatment of Alcohol Dependence
    Medical condition: Alcohol Dependence
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003670-31 Sponsor Protocol Number: BC-10433 Start Date*: 2021-09-22
    Sponsor Name:Ghent University Hospital
    Full Title: Impact of Model-Informed Precision Dosing of Vancomycin in Adults: A randomized, controlled clinical trial
    Medical condition: Gram positive infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003916-10 Sponsor Protocol Number: GR-2021-12372898 Start Date*: 2023-04-21
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease
    Medical condition: IgG4-related disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10071569 Immunoglobulin G4 related sclerosing disease LLT
    21.1 100000004859 10071569 Immunoglobulin G4 related sclerosing disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 01:30:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA